Who are Utidelone plus Intermittent Capecitabine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PLX-200, SPI-2012.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/utidelone-plus-intermittent-capecitabine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Utidelone plus Intermittent Capecitabine — Competitive Intelligence Brief

Utidelone plus Intermittent Capecitabine (Utidelone plus Intermittent Capecitabine) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Plk1 inhibitor. Area: Oncology.

phase 3 Plk1 inhibitor Plk1 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Utidelone plus Intermittent Capecitabine (Utidelone plus Intermittent Capecitabine) — Sun Yat-sen University. Utidelone is a novel, orally administered, small molecule inhibitor of the polo-like kinase 1 (Plk1), which plays a critical role in cell cycle progression and is overexpressed in various cancers.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Utidelone plus Intermittent Capecitabine TARGET	Utidelone plus Intermittent Capecitabine	Sun Yat-sen University	phase 3	Plk1 inhibitor	Plk1
PLX-200	PLX-200	Polaryx Therapeutics, Inc.	phase 3	PLK1 inhibitor	PLK1 (Polo-like kinase 1)
SPI-2012	SPI-2012	Spectrum Pharmaceuticals, Inc	phase 3	PLK1 inhibitor	PLK1 (Polo-like kinase 1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Plk1 inhibitor class)

Sun Yat-sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Utidelone plus Intermittent Capecitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/utidelone-plus-intermittent-capecitabine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab